The San Francisco-based company was founded in 2018 and works with medical researchers and patient advocacy organizations to provide evidence-based therapeutic interventions to patients through their digital platform. The platform is designed to prevent, manage, and treat medical disorders and diseases, making mental health care available to any cancer patient at any time. Blue Note Therapeutics aims to transform care for seriously ill patients by creating clinically-validated, FDA-approvable prescription-only digital devices that are highly effective and engaging for patients and clinicians.